After announcing in March that it was seeking “strategic alternatives” for its future, Seattle publicly-traded biotechnology company Neoleukin Therapeutics is… Read More
— Seattle-based Lighter Capital announced Patricia Elliott as chief sales officer and Kevin Fink as chief technology officer. The “alternative… Read More
Vancouver, B.C.-based Aquinox Pharmaceuticals is set to buy Neoleukin Therapeutics, a Seattle startup that launched out of the University of… Read More
